ANAPTYSBIO, INC. Other Current Liabilities
ANAPTYSBIO, INC. (ANAB) had Other Current Liabilities of $197.00 thousand as of 2021-03-31, per its 10-Q filed 2021-05-04.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2021-05-04
- 2021-03-31: Other Liabilities, Current $197.00K.
- 2020-12-31: Other Liabilities, Current $342.00K.
- 2020-09-30: Other Liabilities, Current $851.00K.
- 2020-06-30: Other Liabilities, Current $925.00K.
| Period end | Other Liabilities, Current |
|---|---|
| 2021-03-31 | $197.00K 10-Q · filed 2021-05-04 |
| 2020-12-31 | $342.00K 10-Q · filed 2021-05-04 |
| 2020-09-30 | $851.00K 10-Q · filed 2020-11-04 |
| 2020-06-30 | $925.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $898.00K 10-Q · filed 2020-05-06 |
| 2019-12-31 | $871.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | $845.00K 10-Q · filed 2019-11-08 |
| 2019-06-30 | $819.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $794.00K 10-Q · filed 2019-05-07 |
| 2018-12-31 | $58.00K 10-K · filed 2020-03-02 |
| 2018-09-30 | $48.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $27.00K 10-Q · filed 2018-08-07 |
| 2018-03-31 | $22.00K 10-Q · filed 2018-05-08 |
| 2017-12-31 | $17.00K 10-K · filed 2019-02-28 |
| 2017-09-30 | $13.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-10 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-12 |
| 2016-12-31 | $1.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |